| Literature DB >> 30377676 |
Abstract
Fiber is an inadequately understood and insufficiently consumed nutrient. This review examines the possible causal relation between fiber-induced microbiome changes and the anti-inflammatory activity of fiber. To demonstrate the dominant role of fermentable plant fiber in shaping the intestinal microbiome, animal and human fiber-feeding studies are reviewed. Using culture-, PCR-, and sequencing-based microbial analyses, a higher prevalence of Bifidobacterium and Lactobacillus genera was observed from the feeding of different types of fermentable fiber. This finding was reported in studies performed on several host species including human. Health conditions and medications that are linked to intestinal microbial alterations likely also change the nutrient environment of the large intestine. The unique gene clusters of Bifidobacterium and Lactobacillus that enable the catabolism of plant glycans and the ability of Bifidobacterium and Lactobacillus to reduce the colonization of proteobacteria probably contribute to their prevalence in a fiber-rich intestinal environment. The fiber-induced microbiome changes could contribute to the anti-inflammatory activity of fiber. Although most studies did not measure fecal microbial density or total daily fecal microbial output (colon microbial load), limited evidence suggests that the increase in intestinal commensal microbial load plays an important role in the anti-inflammatory activity of fiber. Various probiotic supplements, including Bifidobacterium and Lactobacillus, showed anti-inflammatory activity only in the presence of fiber, which promoted microbial growth as indicated by increasing plasma short-chain fatty acids. Probiotics alone or pure fiber administered under sterile conditions showed no anti-inflammatory activity. The potential mechanisms that could mediate the anti-inflammatory effect of common microbial metabolites are reviewed, but more in vivo trials are needed. Future studies including simultaneous microbial composition and load measurements are also important.Entities:
Keywords: fiber; inflammation; intestinal commensal microbial load; microbiome, Bifidobacterium
Year: 2017 PMID: 30377676 PMCID: PMC6201682 DOI: 10.3945/cdn.117.001180
Source DB: PubMed Journal: Curr Dev Nutr ISSN: 2475-2991
Summary of changes in the intestinal microbiome after increasing the intake of fermentable fiber in animal studies
| Effect of fiber on microbiome | ||||||||
|---|---|---|---|---|---|---|---|---|
| Host (age, sex, | Basal diet | Treatment | Duration (d) | Increase | Decrease | Diversity | Density | Ref |
| Mouse | ||||||||
| BALB/c (3 wk, M, 8–11) | No-fiber diet | Supplement 3% FOS/d in tap water | 14CC |
| NA | NA | ↑ | ( |
| C57/BL/6J (9 wk, M, 8) | Purified 35% fat, 26% CHO diet | 10% arabinoxylan mixed with 90% basal diet | 28C |
| NA | NA | ↓ (↑total) | ( |
| ICR (4–6 wk, F, 10) | AIN-93M | 10% rice bran into basal diet | 28F |
| NA | NA | NA | ( |
| BALB/c (adult, F, 10) | 2% guar gum diet | 10% guar gum into basal diet | 14F |
| NA | ↑ | ( | |
| C57/BL/6J (10 wk, M, 10) | Cereal-based 4% fiber diet | Supplement 0.3 g FOS/d in water (∼10% of diet) | 56C | Actinobacteria Proteobacteria Verrucomicrobia | Firmicutes | — | NA | ( |
| BALB/c (8 wk, F, 6) | AIN-93G | 7.5% resistant maltodextrin into basal diet | 14C | CoriobacteriaceaeA | ClostridialesF | NA | NA | ( |
| C57/BL/6J (18 wk, obese M, 6) | AIN-93G-based 45% fat diet | 10% FOS or 10% inulin in basal diet | 28F | CoriobacteriaceaeA | ClostridiaceaeF RuminococcaceaeF | ↓ | NA | ( |
| C57/BL/6N (5 wk, M, 8) | 32% fat diet, plain water | Basal diet and 3% wt:wt AGOS in drinking water | 28F |
|
| NA | NA | ( |
| C57/BL/6J (4 wk, M, 15) | Diet with 45% kcal from fat and supplemented with digestible corn starch | Basal diet with 20% resistant corn starch instead | 70C | LactobacillaceaeF RuminococcaceaeF |
| NA | NA | ( |
| Rat | ||||||||
| Wistar (4 wk, M, 12) | AIN-93G | 1% GOS in basal diet | 14F |
| NA | NA | ↑ | ( |
| Wistar (adult, M, 4–5) | Rapeseed oil and lard-based high-fat diet | 9% pectin or 8% guar gum in basal diet | 21C | Proteobacteria | Bacteroidetes (pectin group only) Firmicutes | ↓ | NA | ( |
| Wistar (4 wk, F, 5) | Purified diet with 5% cellulose | 5% FOS replacing cellulose | 28C | No significant difference in | NA |
| ( | |
| Sprague Dawley (22 wk, F, 14) | High fat/sucrose diet | Basal diet plus 10% wt:wt FOS | 40F (pregnancy & lactation) |
|
| NA | NA | ( |
| Wistar (4 wk, M, 6) | 20% soy protein diet without fiber | 2% soy fiber added in the basal diet | 14C |
|
| NA | NA | ( |
| Pig | ||||||||
| Yorkshire × Hampshire × Landrace (6 wk, MF, 4) | Corn-, soy-based diet | 4% different types of inulin replacing corn starch in basal diet | 35CC |
| NA | NA | NA | ( |
| Duroc × Landrace × | Maize-, soy-based diet | 10% wheat bran or pea fiber replacing 10% maize in basal diet | 30IC |
|
| NA | — | ( |
| Duroc × Landrace × | Maize-, soy-based diet | 10–30% pea fiber replacing 10–30% maize in basal diet | 132C |
| NA | NA | — | ( |
| Shade Oak × Duroc × Hypor (12 wk, MF, 3) | Potato-, soy-based diet | 33% resistant tapioca starch replacing potato starch in basal diet | 84F | ErysipelotrichaceaeF LachnospiraceaeF PrevotellaceaeB VeillonellaceaeF | ClostridiaceaeF | ↓ | NA | ( |
| DanBred × Duroc (10 d, M, 8) | Cereal-based diet | 2% inulin in basal diet | 40CC |
| NA | NA | NA | ( |
| Landrace × | Commercial milk replacer diet | Milk replacer supplemented with 0.8% GOS | 26F |
| NA | NA | — | ( |
| Seghers hybrid × Piétrain (28 d, MF, 6) | Purified fiber-free diet | 5% arabinoxylan replacing corn starch in basal diet | 30C |
| NA | NA | — | ( |
AGOS, agaro-oligosaccharide; CHO, carbohydrate; FOS, fructo-oligosaccharide; GOS, galacto-oligosaccharide; NA, information not available; XOS, xylo-oligosaccharide; —, no effect; ↑, increase; ↓, decrease.
The superscript abbreviation shown after the duration description indicates the sample type used: C, cecal content; CC, cecal and colon content; F, feces; IC, ileum and colon content
List of bacteria follows alphabetical order. The superscript abbreviation shown after each indicates the phylum it belongs to: A, Actinobacteria; B, Bacteroidetes; F, Firmicutes; P, Proteobacteria; V, Verrucomicrobiaceae.
The letter shown after the reference number indicates the method used for microbial analysis: C, CFU determined by plating; G, 16S-rRNA-based denaturing gradient gel electrophoresis; P, quantitative PCR; S, 16S-rRNA-based sequencing and operational taxonomic unit analysis; T, terminal restriction fragment length polymorphism.
Summary of changes in the intestinal microbiome after increasing the intake of fermentable fiber in human subjects of various age groups
| Effect of fiber on microbiome | ||||||||
|---|---|---|---|---|---|---|---|---|
| Type | Cohort | Treatment | Duration | Increase | Decrease | Diversity | Density | Ref |
| Observational study | ||||||||
| Cross-sectional on fibers from different sources | 58 ± 13 y old ( | Self-administered FFQ followed by USDA nutrient database | Before nongastrointestinal or oncologic surgeryF | ClostridiaF (fruit, vegetable) | Porphyromona-daceaeB (bean) | NA | NA | ( |
| Clinical Trial | ||||||||
| Controlled 64% carbohydrate diet supplement | 21–48 y old ( | 15 g FOS/d replacing sucrose in biscuits | 45 d, FOS on days 16–30F |
|
| NA | — | ( |
| Controlled 58–64% carbohydrate diet supplement | 20–34 y old ( | 4 g FOS/d as supplement in tablet and drink | 42 d total, FOS on days 7–32F |
| NA | NA | ↑ | ( |
| Supplement | Fiber: 35–72 y old ( | Fiber group given a mixture of 2.5 g inulin and 2.5 g FOS supplement 3 times/d | 14 d fiber then 1 d colonoscopy preparation dietCO |
| NA | NA | — | ( |
| Randomized double-blind placebo-controlled | 18–45 y old pregnant women: fiber ( | 3 g GOS/FOS 9:1 mix or placebo (6 g maltodextrin), 3 times/d in drink | From 24 to 37 wk of pregnancyF |
| NA | NA | — | ( |
| Randomized double-blind placebo-controlled crossover | 64–79 y old ( | 5.5 g GOS/d or placebo (maltodextrin) in water | 70 d each with 28-d washout in betweenF |
|
| NA | — | ( |
| Randomized double-blind placebo-controlled supplement | Healthy formula-fed infant: fiber ( | Infant formula with or without 6 g GOS/FOS 9:1 mix/L | 6 mo (from birth to 6 mo old)F |
| NA | NA | NA | ( |
| Randomized double-blind placebo-controlled crossover | 20–42 y old ( | 10 g very-long-chain inulin/d or placebo (maltodextrin) in water | 14 d low-pre- and -probiotic diet and then 21 d each with 21-d washout in betweenF |
|
| NA | — | ( |
| Supplement | 21 y old ( | 10 g inulin 2 times/d | 28 dF |
| NA | NA | NA | ( |
| Blind supplement | 19–50 y old ( | 0, 2.5, 5, 10 g GOS/d in chocolate chew (sugar and corn syrup in the control chew) | 21 d each in rising dose, then 14-d washoutF |
|
| NA | ↑ | ( |
| Randomized double-blind placebo-controlled crossover | Men aged 28 ± 4 y ( | 0 or 21 g/d polydextrose or soluble corn fiber in 3 snack bars | 21 d each with no washoutF | ClostridiaceaeF |
| NA | NA | ( |
| Randomized double-blind placebo-controlled | Healthy formula-fed infant: Fiber ( | Infant formula with or without 8 g FOS and inulin 1:1 mix/L | 3 mo (from birth to 3 mo old)F | NA |
| NA | — | ( |
| Randomized double-blind placebo-controlled crossover | 18–65 y old with mean BMI >30 ( | 5.5 g GOS/d or placebo (maltodextrin) in water | 84 d each with 28-d washout in betweenF |
|
| NA | — | ( |
| Controlled 53% carbohydrate diet randomized double-blind crossover | 12–15 y old ( | 0 or 12 g soluble corn fiber supplement/d in 2 meals | 21 d each separated by 7-d washoutF | ClostridialesF |
| — | NA | ( |
| Randomized dose-response double-blind crossover | Females aged 11–14 y ( | 0, 10 or 20 g soluble corn fiber supplement/d, ½ in muffin, ½ in drink (maltodextrin placebo) | 28 d each separated by 28-d washoutF |
|
| ↑ | NA | ( |
| Randomized dose-response double-blind placebo-controlled | 19–56 y old (10/group, total 100) | 0, 5, 10, 20 g HMOs/d or placebo (glucose) as breakfast drink | 14 dF |
| NA | NA | NA | ( |
| Supplement | University undergraduate students | 48 g raw potato starch/d (50% resistant starch) in 2 meal drinks | 7 d after 3-d acclimationF |
| NA | NA | NA | ( |
| Randomized dose-response double-blind | 18–50 y old (8/group, total 24) | 8, 14, 21 g soluble corn fiber/d in 2 beverages | 14 dF |
| NA | NA | — | ( |
| Randomized double-blind placebo-controlled | 45–70 y old, BMI 28–40 ( | 15 g GOS/d or placebo (maltodextrin) in 3 meal drinks | 84 dF |
| NA | NA | NA | ( |
BMI is given in kg/m2. FOS, fructo-oligosaccharide; GOS, galacto-oligosaccharide; HMO, human milk oligosaccharides, 2′-O-fucosyllactose, lacto-N-neotetraose, or mix of the 2; NA, information not available; —, no effect; ↑, increase; ↓, decrease.
Cohorts included both genders unless indicated otherwise.
In observational study, this column shows fiber intake measurement.
In observational study, this column shows the study population. The superscript abbreviation shown after the study duration description indicates the sample type used: CO, colon content collected during colonoscopy; F, feces.
List of bacteria follows alphabetical order. The superscript abbreviation shown after each indicates the phylum it belongs to: A, Actinobacteria; B, Bacteroidetes; F, Firmicutes; FU, Fusobacteria; P, Proteobacteria.
The letters shown after the reference number indicate the method used for microbial analysis. C: CFU determined by plating; CH, human intestinal tract chip; F, 16S rRNA-based FISH (fluorescence in-situ hybridization) analysis; G, 16S-rRNA-based denaturing gradient gel electrophoresis; P, quantitative PCR; S, 16S-rRNA-based sequencing and operational taxonomic unit analysis.
Summary of observations on the intestinal microbiome changes that can at least be partially explained by the intestinal nutrient environment
| Host | Method | Observations on the intestinal microbiome (ref) | Intestinal nutrient environment as a factor (ref) |
|---|---|---|---|
| Dietary pattern | |||
| M | S | Feeding salmon cartilage proteoglycan led to alteration in the intestinal microbiome ( | Proteoglycan can be used by intestinal commensal as a substrate ( |
| M | S | Fruit or nut supplementation led to microbiome changes such as increases in | Fruits and nuts are good dietary sources of fermentable fibers and other prebiotic compounds ( |
| H,M,P | S | High-fat diet led to changes such as the depletion of | High-fat diet led to lower intake of fermentable fiber and thus a lower fiber presence in the intestine ( |
| Development and aging | |||
| H | A, P | Fraternal twins shared developmental changes ( | Twins likely given the same breast milk, formula, and solid food |
| H | P, S | Breastfed and formula-fed infants did not have consistent differences in intestinal microbiome from study to study ( | The composition of breast milk and infant formula can be different from study to study so the impact on the intestinal microbiome varied |
| H | S | Infant gut microbiome developed features of the adult microbiome upon switching to table food ( | Infant microbiome had functional genes for the metabolism of polysaccharide in table food prior to the diet switching ( |
| H | S | Different birth delivery modes led to transient but not long-term difference in microbiome ( | The effect of delivery mode was overridden by later-life dietary factors which then contribute to the interindividual variations ( |
| H | S | Elderly in long-term care facility has less microbiome diversity and the composition correlates with residence location ( | Residents in each long-term care facility have limited but quite uniform food choices and the food choices could be different between facilities ( |
| Disease and medication | |||
| H | C, G, P, S, T | Patients with IBD have altered intestinal microbiome such as a decrease in Bacteroidetes and Firmicutes and higher γ-Proteobacteria ( | IBD could lead to different dietary patterns ( |
| H | M, S | Patients using PPIs showed decreased diversity and higher presence of oral bacteria ( | PPI users have different dietary pattern ( |
Hosts included both sexes. A, microarray; C, bacterial culturing; G, 16S-rRNA-based denaturing gradient gel electrophoresis; H, human; IBD, inflammatory bowel disease; M (method), megagenomic sequencing analysis; M (host), mouse; P (method), qPCR; P (host), primate; PPI, proton pump inhibitor; ref, reference; S, 16S rRNA sequencing and operational taxonomic unit analysis; T, terminal restriction fragment length polymorphism.